Page 105 - Memoria FEHH - SEHH 2017

PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Niculescu L, Anderson KC, Lonial S, Richardson PG. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma:towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017 Aug; 178(4):547-60. PMID: 28466536.
• Martínez-López J, Sánchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marín C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jiménez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martín- Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, García-Sanz R, Lahuerta JJ. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia. 2017 Jun;31(6):1446-9. PMID: 28210002.
• Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martínez-López J, Cordón L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutiérrez NC, Hernández MT, Oriol A, Echeveste MA, González Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017 Feb;31(2):382-92. PMID: 27479184.
• Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R. A Next- Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. J Mol Diagn. 2017 Jan;19(1):99-106. PMID: 27863261.
Presentaciones orales en congresos internacionales
• Mateos MV, Martínez-López J, Hernández M, Martínez R, Rosiñol L, Ocio EM, Pérez de Oteyza J, Oriol A, Bargay J, Gironella M, Martín J, Cabrera C, de la Rubia J, Puig N, Paiva B, Cedena MT, Rodríguez-Otero P , Blade J, Lahuerta JJ, San Miguel JF. Depth of response as surrogate marker for progression-free survival and overall survival in elderly newly diagnosed myeloma patients treated with VMP and RD: GEM2010MAS65. 22th Congress of the EHA 2017. Madrid, June 2017. Haematologica. 2017 Jun 11;102(s2):S409.
• Rodríguez Otero P, Mateos MV, Orlowski R, Siegel D, Reece D, Moreau P, Ocio EM, Munshi N, Avigan D, Ghori R, Wnek R, Mogg R, Marinello P, San Miguel J. Pembrolizumab plus lenalidomide and low-dose dexamethasone for pa- tients with relapsed/refractory multiple myeloma: efficacy and biomarker results from the phase 1 Keynote-023 study. 22th Congress of the EHA 2017. Madrid, June 2017. Haematologica. 2017 Jun 11;102(s2):S783.
• Rosiñol L, Oriol A, Ríos R, Sureda A, Blanchard MJ, Hernández M, Martínez R, Moraleda JM, Jarque I, Bargay J, Giro- nella M, Moreno MJ, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado F, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J. Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial. 59th ASH Annual Meeting. At- lanta, December 2017. Blood. 2017;130:2017.
• Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genescà E, Martínez-Carba- lleira D, Martino R, Vives S, Guàrdia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llobera F, Ribera J, Martínez-Sánchez P, Amigó ML, Bermúdez A, Calbacho M, Hernández-Rivas JM, Feliú E, Ribera JM. Is the outcome of patients with High Risk T-Cell acute lymphoblastic leukemia improving in the Era of pediatric- inspired protocols? A comparison of 2 consecutive Pethema Trials. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:1323.
105